Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956809 · ClinicalTrials.gov registry record · Phase 2
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
A Phase 2 study of HFrEF, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT04956809: Completed Phase 2 study of HFrEF, sponsored by University of Pennsylvania.
NCT04956809 is a Phase 2 study of HFrEF that has completed, run by University of Pennsylvania. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04956809, a Phase 2 study of HFrEF, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10Mg Tab
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
What the finished NCT04956809 record still lists
NCT04956809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with HFrEF appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04956809 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04956809 about?
NCT04956809 is a clinical study titled "Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure". This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
What is the current status of trial NCT04956809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-10-22. Estimated completion is 2023-06-01.
What conditions does trial NCT04956809 study?
This clinical trial studies the following conditions: HFrEF.
What interventions are being tested in trial NCT04956809?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10Mg Tab (DRUG).
Who is sponsoring clinical trial NCT04956809?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04956809 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04956809's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI